In a joint effort with Ricoh Americas Corporation*, BBK Worldwide, Inc., announces the expansion of its production facility to include full-service, in-house distribution services, called Distribution Central. These services were developed to reduce the time-to-market for production and distribution of communications materials to the clinical research sites.
BBK is committed to making the same robust tools currently available to study sites in the United States, available to study sites throughout the world. Distribution Central complements BBK's cultural adaptation, translation and variable in-house printing capabilities.
In addition to Distribution Central, BBK will be introducing an online document management system designed specifically to track recruitment and retention materials for clinical trials. Starting in October, BBK will be taking on full responsibility for regulatory submissions globally, and managing direct distribution to study sites on an expedited basis.
Clinical trial sponsors in need of assistance with any aspect of material development–from creative concepts, to development and production, to delivery at an investigator's doorstep–can contact BBK at (617) 630-4477 or info@bbkworldwide.com.
*Ricoh Americas Corporation is the US arm of Ricoh Company, Ltd., Japan.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.